Title of the cohort

Cohort – H85

Acronym for cohort


Name of Principal Investigator
Title Professor
First name Ingmar
Last name Skoog
Address of institution where award is held
Institution Neuroscience and Physiology, Neuropsychiatric Epidemiology
Street Address Wallinsgatan 6
Postcode SE-431 41
  • Sweden


Contact email
Funding source

1) The Swedish Research Council (VR).
2) Swedish Council for Working Life and Social Research (FAS).
3) The US Alzheimer’s Association.

1. The cohort includes, or expects to include, incidence of the following conditions
  • Alzheimer’s disease and other dementias
  • Parkinson’s disease
  • Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible
  • 2011 – 2015
2a. Stated aim of the cohort

To study dementia and other mental disorders (depression, psychotic disorders, anxiety disorders) in longitudinally followed elderly populations from different birth cohorts.

2b. Features distinguishing this cohort from other population cohorts

The possibility to compare 85-year-olds examined 22 years apart, and the comprehensive examinations.

3a. i) Number of publications that involve use of cohort to date


3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)


3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
Age in years from: 85
To (‘until death’ if applicable): 107
4b. Study criteria: inclusion criteria

Aged 85 and born 1901-02 or 1923-24 on certain dates, and living in Gothenburg, Sweden

4c. Study criteria: exclusion criteria


5. Size of the cohort (i.e. number of participants enrolled)
  • 1,000 – 5,000 participants
6a. Measures used to characterise participants

psychiatric examinations, close informant interviews, psychometric testings, ADL, social factors, personality inventories, physical examinations, DNA-analyses, comprehensive laboratory tests, CT-scan of the head, cerebrospinal fluid analyses and case record studies. (see also www.epinep.gu.se)

6b. Additional measures for participants with a clinical disorder


6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

Dementia and other psychiatric disorders

7. Study design
  • Prospective cohort
  • Retrospective cohort
  • Longitudinal
  • Cross sectional survey
8. Cases matched by


9a. Does the study include a specialised subset of control participants
  • No
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date


10a. ii) Data collection end date


10a iii) Data collection for this study is
  • Data collection ongoing
  • Data analysis ongoing
10b. Plans to continue the cohort study beyond the current projected end date
  • Yes – funding applied for
  • Yes – intend to apply for funding
11. Data collected
  • Only through the study
  • Through links to medical records
12. System in place to enable re-contact with patients for future studies
  • Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database
Yes/No % available
Data summarised in database  Yes  100
Database is web-based  No
Database on spreadsheet  Yes
Database is on paper  Yes
Other (specify)


Language used:


13b. Format and availability of data held as individual records
Yes/No % available
Data held as individual records  Yes  100
Data is web-based No
Data held on computer based records  Yes  100
Data held on cards  No
Other (specify)


Language used:


14a. Are data available to other groups


14b. Access policy/mechanisms for access if data are available to other groups
  • Apply to PI or co-ordinator at resource
  • Access through collaboration with PI only
15. Data sharing policy specified as a condition of use
  • No requirement to make data publicly available
16a. Are tissues/samples/DNA available to other groups


16b. i) Description of available tissues/samples/DNA
  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: cerebro-spinal fluid
  • Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
  • Primary samples: Supplied fresh
  • Primary Samples: Stabilised samples (frozen or fixed)
  • Secondary samples: plasma
  • Secondary samples: DNA
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data


17. Is information on biological characteristics available to other groups
  • Yes, for all the cohort

Types: Population Cohorts
Member States: Sweden
Diseases: Alzheimer's disease & other dementias, Neurodegenerative disease in general, Parkinson's disease & PD-related disorders
Years: 2011
Database Categories: N/A
Database Tags: N/A

Export as PDF